Circulating miR-31 as an effective biomarker for detection and prognosis of human cancer: a meta-analysis

Ying, Ma; Chen, Yunfang; Lin, Jinbo; Liu, Yi; Luo, Kai; Cao, Yong; Wang, Tieqiang; Jin, Hongwei; Su, Zhan; Wu, Haolin; Chen, Xiaoliang; Cheng, Jinquan

doi:10.18632/oncotarget.15638

Cited by 12 publications

(10 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, we found a correlation between low miR-31 serum concentration and a longer survival. In a meta-analysis of 14 different studies including different tumor types, a significant correlation between low miR-31 concentration in blood and a longer overall survival was shown [ 35 ]. Studies in tumor biopsies confirm that a low miR-31 expression correlates with a longer overall survival [ 49 ].…”

Section: Discussionmentioning

confidence: 99%

“…A set of 5 miRNAs (mir-17, mir-660, mir-92a, mir-106a, and mir-19b) is most commonly dysregulated in serum and tumor tissue samples from lung cancer patients and has therefore promising diagnostic potential [ 34 ]. In a meta-analysis circulating miR-31 was determined as an effective biomarker for cancer detection and prognosis [ 35 ]. MiRNAs may also be markers for therapy resistance.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Association between miRNA signatures in serum samples from epidermal growth factor inhibitor treated patients and skin toxicity

et al. 2021

View full text Add to dashboard Cite

Objective: Epidermal growth factor receptor inhibitors (EGFRI) are used as targeted cancer therapy. On average 70% of patients treated with EGFRIs suffer from skin toxicity. Studies showed a correlation between overall survival and the appearance of a skin rash, which is used as a biomarker for therapy efficacy. Micro RNAs (miRNA) as tumor or resistance biomarkers for cancer therapy are also highly investigated. In our study, we searched for associations of miRNA expression profiles in serum, with the severity of skin rash, in order to identify tentative therapy predictive biomarkers.Materials and Methods: Five candidate miRNAs were selected, based on an earlier in vitro next-generation-sequencing-experiment and after literature search. MiR-21, miR-31, miR-17, miR-106b and miR-520e were investigated in serum samples from patients (n = 254) treated with EGFRI. The quantitative expression of miRNA was tested for association with the occurrence/severity of the rash.Results: In our cohort of patients treated with EGFR inhibiting monoclonal antibodies, miR-21 and miR-520e serum concentrations were negatively correlated with severity of skin rash (p-value 0.000582 and 1.53e-07 linear-trend-test) whereas for miR-31, a positive correlation was observed (p-value 9.01e-06 linear-trend-test).Conclusions: This suggests that miR-21, miR-31 and miR-520e expression might be a treatment dependent marker for EGFRI induced skin rash.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Association between miRNA signatures in serum samples from epidermal growth factor inhibitor treated patients and skin toxicity

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Emerging evidence has indicated that miR-31-5p is upregulated and acts as an oncogenic miRNA in a wide variety of neoplasms,40, 41, 42 including oral cancer 41 . Meta-analyses indicated that high miR-31-5p expression is associated with a poor overall survival (OS) in patients with general cancers and that miR-31-5p may be a useful clinical prognostic biomarker 43, 44. Moreover, in the 4-nitroquinoline-1-oxide (4NQO)-induced mouse tongue carcinogenesis model, Kao et al 45 .…”

Section: Discussionmentioning

confidence: 99%

miR-31-5p Is a Potential Circulating Biomarker and Therapeutic Target for Oral Cancer

Liang

et al. 2019

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

MicroRNAs have been proposed as novel biomarkers for the diagnosis and treatment of many types of cancer. The levels of five candidate microRNAs (miRNAs) (miR-99a-5p, miR-31-5p, miR-138-5p, miR-21-5p, and miR-375-3p) in sera from oral cancer patients and paired tumor and normal tissues were detected by real-time qPCR. The diagnostic power of these miRNAs was analyzed by receiver operating characteristic (ROC) curves. Patient-derived xenograft (PDX) models of oral cancer were established and utilized to verify the potential therapeutic effect of miR-31-5p. Candidate miRNAs were screened from our previous studies and verified in 11 paired oral cancer and adjacent normal tissues. Only serum miR-31-5p levels were significantly different between oral cancer patients and healthy controls and between pre- and postoperative patients. Based on the logistic regression model, this panel of five miRNAs distinguished oral cancer patients from healthy control, with an area under the ROC curve (AUC) of 0.776 (sensitivity = 76.8% and specificity = 73.6%). Furthermore, a miR-31-5p mimic enhanced the proliferation of normal epithelial cells, and antagomiR-31-5p inhibited the proliferation of oral cancer cells in vitro . In vivo , antagomiR-31-5p significantly inhibited tumor growth in oral cancer PDX models. Our findings suggest that circulating miR-31-5p might act as an independent biomarker for oral cancer diagnosis and could serve as a therapeutic target for oral cancer.

show abstract

“…Mir-31 has been shown to have oncogenic influence ( 51 ) and the potential as a biomarker for detection and to monitor treatment response and prognosis ( 52 – 55 ). Along with miR-135b-5p, miR-31-3p has also been shown by our lab to be upregulated in tumor tissue of HNSCC patients compared with adjacent normal tissue ( 56 ).…”

Section: Discussionmentioning

confidence: 99%

Blood Serum From Head and Neck Squamous Cell Carcinoma Patients Induces Altered MicroRNA and Target Gene Expression Profile in Treated Cells

et al. 2018

View full text Add to dashboard Cite

The head and neck squamous cell carcinoma (HNSCC) represents one of the most common cancers in humans. Close to 600,000 new diagnoses are made every year worldwide and over half of diagnosed patients will not survive. In view of this low survival rate, the development of novel cell-based assays for HNSCC will allow more mechanistic approaches for specific diagnostics for each individual patient. The cell-based assays will provide more informative data predicting cellular processes in treated patient, which in effect would improve patient follow up. More importantly, it will increase the specificity and effectiveness of therapeutic approaches. In this study, we investigated the role of serum from HNSCC patients on the regulation of microRNA (miRNA) expression in exposed cells in vitro. Next-generation sequencing of miRNA revealed that serum from HNSCC patients induced a different miRNA expression profile than the serum from healthy individuals. Out of 377 miRNA detected, we found that 16 miRNAs were differentially expressed when comparing cells exposed to serum from HNSCC or healthy individuals. The analysis of gene ontologies and pathway analysis revealed that these miRNA target genes were involved in biological cancer-related processes, including cell cycle and apoptosis. The real-time PCR analysis revealed that serum from HNSCC patients downregulate the expression level of five genes involved in carcinogenesis and two of these genes—P53 and SLC2A1—are direct targets of detected miRNAs. These novel findings provide new insight into how cancer-associated factors in circulation regulate the expression of genes and regulatory elements in distal cells in favor of tumorigenesis. This has the potential for new therapeutic approaches and more specific diagnostics with tumor-specific cell lines or single-cell in vitro assays for personalized treatment and early detection of primary tumors or metastasis.

show abstract

Circulating miR-31 as an effective biomarker for detection and prognosis of human cancer: a meta-analysis

Cited by 12 publications

References 50 publications

Association between miRNA signatures in serum samples from epidermal growth factor inhibitor treated patients and skin toxicity

Association between miRNA signatures in serum samples from epidermal growth factor inhibitor treated patients and skin toxicity

miR-31-5p Is a Potential Circulating Biomarker and Therapeutic Target for Oral Cancer

Blood Serum From Head and Neck Squamous Cell Carcinoma Patients Induces Altered MicroRNA and Target Gene Expression Profile in Treated Cells

Contact Info

Product

Resources

About